Epithalon Peptide: What the Evidence Shows and Who It's For (2026 Guide)

Executive Summary

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin — a natural polypeptide extract from the pineal gland. It was developed in the 1980s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, who spent the following four decades studying its effects on aging, longevity, and biological regulation in both animals and humans. What makes Epithalon unusual among longevity peptides is the breadth and duration of its research base. Most peptides entering the anti-aging market have animal studies and mechanistic data. Epithalon has those plus long-term human studies showing measurable effects on telomere length, mortality rates, and biomarkers of aging — making it one of the most evidence-backed interventions available for biological aging.

The core mechanism is telomerase activation. Telomerase is an enzyme that extends telomere length — and telomere shortening is one of the primary hallmarks of biological aging. Epithalon appears to activate telomerase expression in human somatic cells, potentially slowing the telomere attrition that drives cellular senescence. It also regulates melatonin secretion from the pineal gland, which affects sleep quality, circadian rhythm, and the broader hormonal environment that governs aging. This guide covers what the evidence actually shows, how Epithalon compares to other longevity peptides, what protocols are used in clinical practice, and how to access pharmaceutical-grade Epithalon in 2026. For context on how Epithalon fits within a complete anti-aging peptide stack, see our peptide therapy for anti-aging overview and our complete beginner's guide to peptide therapy.

At-a-Glance Comparison

Epithalon evidence summary based on published research as of 2026. Evidence grade reflects quality and volume of available data across human, animal, and in vitro research.

What Is Epithalon and How Does It Work?

Epithalon's mechanism is unusually well-characterized for a peptide — understanding it explains why the research findings are biologically coherent rather than speculative. Buyers searching for epithalon peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Epithalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine). It was synthesized as a shorter, more stable analogue of epithalamin — a complex polypeptide extract from bovine pineal glands that Vladimir Khavinson's team at the St. Petersburg Institute of Bioregulation had been studying since the 1970s. The core mechanism Khavinson's group identified is telomerase activation. Telomerase (hTERT) is the enzyme responsible for extending telomere length in dividing cells. In somatic (non-stem) cells, telomerase is largely suppressed — meaning each cell division shortens telomeres slightly. When telomeres reach a critical minimum length, cells enter senescence or apoptosis. This progressive telomere shortening is one of the primary molecular drivers of biological aging and is associated with age-related disease risk. Epithalon appears to induce expression of the telomerase catalytic subunit (hTERT) in human somatic cells, allowing those cells to partially restore telomere length rather than continue shortening with each division. In a landmark 2003 paper by Khavinson et al. published in Bulletin of Experimental Biology and Medicine, Epithalon treatment of human fetal fibroblasts extended their replicative capacity (Hayflick limit) by approximately 42% and activated telomerase expression in cells where it was previously suppressed. The pineal gland regulatory mechanism is the second major pathway. Epithalon is derived from an epithalamin extract that specifically targets pineal function — and the pineal gland is the master regulator of melatonin secretion, circadian rhythm, and a number of neuroendocrine signals that coordinate aging biology. In aging animals and humans, pineal function declines, melatonin output falls, and the circadian melatonin rhythm flattens. Epithalon administration in elderly human subjects and in animal models consistently restores melatonin secretion and circadian rhythm amplitude. For the broader context of how Epithalon fits in a complete peptide anti-aging stack, see our peptide therapy for anti-aging guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: conflating the mechanistic and animal data with proven human longevity outcomes — the telomerase activation and animal lifespan extension data are strong, but human randomized controlled trials specifically for longevity outcomes do not exist. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The Clinical Evidence: What the Research Actually Shows

Epithalon has more published research than almost any other longevity peptide. Here's what the data shows across the primary outcomes. Buyers searching for epithalon peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The research on Epithalon spans in vitro, animal, and human studies — with an unusually long research tradition dating back to Khavinson's work in the 1980s. Telomere and cellular aging evidence: A 2003 Khavinson et al. study in human fetal lung fibroblasts showed Epithalon (at 0.1–100 ng/mL) activated telomerase expression and extended the replicative lifespan of cells by an average of 42.5% compared to controls. The cells treated with Epithalon survived to 44 population doublings versus 31 in controls — a significant extension of the Hayflick limit. This has been replicated in subsequent in vitro studies including human epithelial cells, where Epithalon similarly activated hTERT expression in otherwise senescent cells. Animal longevity studies: Vladimir Anisimov and colleagues conducted a series of landmark murine studies using Epithalon (as well as epithalamin) that showed consistent lifespan extension. A 2006 study in the Annals of the New York Academy of Sciences demonstrated that Epithalon treatment extended mean lifespan of female rats by 25% and of male rats by 18% versus controls. A separate study in transgenic HER-2/neu mice (a breast cancer model) showed Epithalon delayed tumor development and reduced tumor incidence. Across multiple species and models, Epithalon consistently shows 18–40% extension of mean lifespan in controlled animal experiments — a remarkably consistent finding across decades of independent replication. Human studies: A 15-year follow-up study by Khavinson's group followed elderly patients (60–80 years) who had received epithalamin (the precursor to synthetic Epithalon) versus controls. The treated group showed significantly lower mortality (28% lower over the follow-up period), lower incidence of cardiovascular disease and respiratory illness, and better maintenance of melatonin secretion and T-cell immune markers. While this was an observational study rather than a blinded RCT, the duration and consistent findings make it one of the most compelling long-term human datasets available for any longevity peptide. Melatonin restoration: Multiple human studies in elderly subjects show Epithalon administration significantly increases nighttime melatonin secretion and restores the normal circadian amplitude of melatonin secretion. In one study of elderly patients with low baseline melatonin, Epithalon treatment more than doubled nighttime melatonin levels. For the context of how Epithalon compares to NAD+ therapy and other anti-aging interventions, see our NAD+ therapy complete guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: treating Epithalon as a proven human longevity drug — the animal and mechanistic evidence is compelling, the human observational data is encouraging, but double-blind RCTs in humans for longevity outcomes do not exist for any single intervention, including Epithalon. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Epithalon vs. Other Longevity Peptides: How It Compares

Epithalon occupies a distinct niche in the longevity peptide space — understanding how it compares to other interventions helps clarify when to prioritize it. Buyers searching for epithalon peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Epithalon addresses aging through telomere biology and neuroendocrine regulation — a different mechanism from most other popular longevity peptides and interventions. vs. GHK-Cu: GHK-Cu (copper peptide) targets collagen synthesis, tissue repair, and inflammatory gene regulation. It has strong evidence for skin and wound healing outcomes in humans. Epithalon targets cellular replication limits and circadian/hormonal aging. These mechanisms are highly complementary — many comprehensive anti-aging protocols combine both. GHK-Cu has more human topical evidence; Epithalon has more direct longevity/telomere evidence. For detailed GHK-Cu information, see our GHK-Cu peptide guide. vs. BPC-157 and TB-500: BPC-157 and TB-500 are primarily acute repair and recovery peptides — targeting muscle, tendon, gut, and neurological tissue repair. Epithalon is a longevity and anti-aging peptide working through fundamentally different mechanisms (telomerase, pineal). There is minimal mechanism overlap. An anti-aging-focused protocol might combine Epithalon for longevity signaling with BPC-157 or TB-500 for tissue repair. vs. Growth hormone secretagogues (sermorelin, ipamorelin, CJC-1295): GH peptides work through the GH/IGF-1 axis, driving anabolic metabolism, muscle protein synthesis, and GH-mediated tissue repair. Epithalon has no GH axis involvement. A comprehensive longevity protocol might combine GH secretagogues for body composition and anabolic maintenance with Epithalon for telomere and neuroendocrine regulation. For the GH peptide comparison, see our sermorelin vs ipamorelin vs CJC-1295 guide. vs. NAD+ therapy: NAD+ works through the sirtuin and PARP pathways — mitochondrial function, DNA repair, and metabolic aging. Epithalon works through telomerase activation and pineal regulation. Again, distinct but complementary mechanisms — some longevity medicine practitioners combine both. NAD+ has more mainstream clinical adoption; Epithalon has a longer and more specific research history for telomere biology. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: expecting Epithalon to replace GH peptides or NAD+ therapy — it addresses a specific and distinct aging pathway; the strongest protocols combine multiple mechanistically complementary interventions. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Epithalon Dosing Protocols: What Clinical Practice Shows

There is no FDA-approved dosing standard — clinical protocols are based on the research literature, Khavinson's published protocols, and physician experience. Buyers searching for epithalon peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Epithalon is not FDA-approved for any indication, and dosing protocols used in clinical practice are derived from the research literature and the Russian clinical experience from Khavinson's group. The most commonly referenced research protocols and their adaptations in clinical longevity medicine are: Standard research protocol: 10 mg per day, administered subcutaneously or intranasally, for 10–20 consecutive days. This protocol was used in Khavinson's human studies and forms the basis for most clinical adaptations. At 10 mg/day for 10 days, total cycle dosing is 100 mg. Typical clinical longevity protocol: Many longevity medicine physicians in the US now prescribe Epithalon as 10 mg per day subcutaneously for 10 days, once or twice per year — sometimes called a "longevity cycle." The rationale for annual or semi-annual cycles rather than continuous use is based on the animal research protocols and the hypothesis that cycled exposure is sufficient for telomerase activation without requiring chronic continuous dosing. Lower dose daily protocol: Some practitioners use 1–5 mg per day subcutaneously for extended periods (30–60 days) with longer rest periods between cycles. This is less studied but follows the general peptide cycling principle of maintaining periodic on/off cycling. Intranasal route: Some protocols use intranasal administration as a non-injection alternative. Bioavailability via intranasal delivery is lower and less predictable than subcutaneous, but it's used by practitioners who want to avoid injection protocols. Typical intranasal doses are 2–5 mg per day via nasal spray. Onset and timing: Melatonin-related improvements (better sleep quality, restored circadian rhythm) are often among the earliest subjective effects reported — sometimes within the first week of a cycle. Cellular aging effects (telomere length changes, biomarker improvements) are not perceptible subjectively and would require laboratory measurement over months to years. For context on peptide cycling principles broadly, see our peptide therapy beginner's guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: assuming that more frequent or higher doses produce proportionally better outcomes — the research doesn't support continuous chronic dosing; the cycled protocols used in research and clinical practice are deliberate, not limitations. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Safety Profile and Side Effects

With 40+ years of research and human clinical use, Epithalon has an unusually well-characterized safety profile — here's what the evidence shows. Buyers searching for epithalon peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Epithalon has been studied extensively in both animal models and human subjects over four decades by Khavinson's group and independently — making its safety profile better characterized than most longevity peptides. Animal safety data: Across decades of animal studies including long-term lifespan studies (multiple years in rodents), no significant toxicological signals have been identified. Epithalon does not appear to produce organ toxicity, immune suppression, or tumor-promoting effects at standard doses — in fact, the animal data shows reduced tumor incidence rather than increased. Human safety data: Khavinson's human studies (including the 15-year follow-up) report no significant adverse events from Epithalon use at standard protocol doses. The most commonly reported side effects in clinical practice are mild and transient: injection site irritation (redness, minor discomfort), headache in a small minority of users, and occasional vivid dreams attributed to melatonin normalization. No serious adverse events attributable to Epithalon have been published in the peer-reviewed literature. Theoretical concerns: Telomerase activation raises a theoretical concern about cancer risk — telomerase is also activated in cancer cells, allowing them to replicate indefinitely. This is a mechanistically reasonable concern. However, Epithalon's animal data consistently shows reduced tumor incidence rather than increased, suggesting that physiological telomerase activation in healthy somatic cells (restoring a partial, regulated telomerase function) is different from the dysregulated constitutive telomerase overexpression in cancer cells. This remains an important nuance to understand — Epithalon is not recommended for individuals with active cancer or a strong personal/family history of cancer without careful discussion with a qualified physician. Drug interactions: No significant documented drug interactions. Epithalon does not affect cytochrome P450 enzymes and does not bind to common drug targets at standard doses. Product quality is the primary practical safety concern: Pharmaceutical-grade compounded Epithalon from a licensed compounding pharmacy is essential for injectable use — unverified research chemical suppliers carry significant sterility and concentration accuracy risks. For safety guidance on peptide therapy broadly, see our peptide therapy safety guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: using Epithalon in individuals with active malignancy or high cancer risk without physician oversight — the theoretical telomerase-cancer concern makes medical screening important despite the generally favorable animal evidence. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Who Is Epithalon Best Suited For?

Epithalon is not for everyone — understanding the ideal candidate profile helps set appropriate expectations. Buyers searching for epithalon peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Based on the research profile and clinical use patterns, Epithalon is best suited for a specific subset of people interested in longevity medicine: The ideal candidate for Epithalon is someone who: Is 40+ years old and proactively focused on biological aging and longevity. Has already addressed the foundational health drivers (sleep quality, strength training, metabolic health, nutrition). Is interested in comprehensive longevity protocols — not looking for a single-intervention shortcut. Has access to medical supervision and pharmaceutical-grade compounded peptide. Wants an anti-aging intervention with the longest and deepest research base in the peptide space. Epithalon is likely not the right starting point for: Someone new to longevity optimization who hasn't addressed sleep, exercise, and metabolic health first. Someone seeking acute improvements in body composition, energy, or physical performance (GH peptides or testosterone optimization are better fits). Someone under 40 with no specific telomere or pineal regulation concerns. Someone who cannot access medical supervision and pharmaceutical-grade peptide. Epithalon's strongest use cases in practice: Men over 50 who are building a comprehensive longevity protocol alongside GH peptides, NAD+ therapy, and hormonal optimization. Men experiencing degraded sleep quality and melatonin disruption as part of aging who want targeted pineal regulation beyond standard melatonin supplementation. Individuals with longevity as a primary health objective who want the peptide with the longest and deepest evidence base for cellular aging mechanisms. For a guide to what foundational longevity protocols typically look like, see our TRT complete guide for hormonal optimization context or our NAD+ therapy guide for metabolic aging context. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: using Epithalon as a substitute for foundational longevity behaviors (sleep, resistance training, metabolic health) rather than as an adjunct to them — it addresses a specific molecular mechanism, not overall health. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

How to Access Epithalon in 2026: Clinics, Sourcing, and Cost

Epithalon occupies a unique access landscape — it's available through US longevity clinics but is not mainstream; here's how to navigate it. Buyers searching for epithalon peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Epithalon is not FDA-approved and is not available as a standard pharmaceutical. In the US, it is accessed through compounding pharmacies that manufacture it under the 503A compounding exemption — requiring a prescription from a licensed physician. Online longevity and peptide clinics: A growing number of online longevity medicine practices in the US offer Epithalon as part of their anti-aging peptide protocols. These typically include a physician consultation, review of lab work and health history, and a prescription for compounded Epithalon from a licensed compounding pharmacy. Not all online peptide clinics that offer sermorelin, ipamorelin, or BPC-157 also offer Epithalon — it's a more specialized offering. Clinics with dedicated longevity medicine or bioregulatory peptide programs are the most likely source. Typical cost: Compounded Epithalon for a standard 10-day cycle (10 mg/day × 10 days = 100 mg total) typically costs $150–$400 depending on the clinic and compounding pharmacy. Annual protocols running two cycles per year would typically cost $300–$800 total for the peptide — plus any ongoing consultation costs with the prescribing physician. International access: Epithalon is widely used in European longevity clinics, particularly in Germany, the UK, and Eastern Europe where bioregulatory peptide therapy (following Khavinson's protocols) has been in mainstream clinical use longer than in the US. Some patients access international clinic protocols for combined bioregulatory peptide treatments. What to look for in a provider: A provider familiar with Epithalon specifically (not just general peptide prescribers). Pharmaceutical-grade compounded peptide from a US-licensed 503A compounding pharmacy. Clear dosing protocol aligned with the published research (10 mg/day for 10–20 days, cycled 1–2x annually). Willingness to monitor biomarkers before and after cycles. For a guide to the top online peptide clinics, see our best peptide clinics online (2026) or compare providers directly using our provider comparison tool. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: sourcing Epithalon from unverified research chemical suppliers — injectable peptides require pharmaceutical-grade manufacturing for safety and purity; research chemicals sold outside the medical system cannot be verified for sterility, purity, or concentration. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Epithalon protocols require a physician experienced with bioregulatory peptides and compounded longevity peptides. Not all online peptide clinics offer Epithalon — look for clinics with dedicated longevity medicine programs. Use our provider comparison tool to find clinics that offer the right protocols.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is Epithalon peptide?

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a natural polypeptide from the pineal gland. It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and has been studied for over 40 years as a longevity and anti-aging intervention. Its primary mechanisms are telomerase activation (which may slow telomere shortening in aging cells) and pineal gland regulation (restoring melatonin secretion and circadian rhythm in aging individuals).

What does Epithalon do?

Epithalon's primary documented effects are: (1) activating telomerase in human somatic cells, potentially slowing the telomere shortening that drives cellular senescence; (2) stimulating melatonin production from the pineal gland, restoring circadian rhythm and improving sleep quality in aging individuals; and (3) reducing tumor incidence and improving immune markers in animal longevity models. Long-term human observational data shows lower mortality and morbidity rates in treated elderly groups.

What is the correct Epithalon dosage?

The most commonly used clinical protocol is 10 mg per day administered subcutaneously for 10–20 consecutive days, repeated once or twice per year. This protocol is based on Khavinson's published research protocols. Some practitioners use lower doses (1–5 mg/day) for longer cycles. Intranasal delivery is used as a non-injection alternative at 2–5 mg/day but has lower and less predictable bioavailability.

Is Epithalon safe?

Based on 40+ years of animal studies and human clinical use, Epithalon has not produced significant adverse events in the published literature. Common minor side effects in clinical practice include injection site irritation and occasional headache. The primary theoretical safety concern is that telomerase activation could theoretically promote cancer cell replication — but Epithalon's actual animal data shows reduced tumor incidence, not increased. Individuals with active cancer should discuss with a physician before use. Product quality is the main practical safety variable — pharmaceutical-grade compounded peptide from a licensed pharmacy is essential.

How often should you take Epithalon?

Most clinical protocols use Epithalon in annual or semi-annual cycles rather than continuously. A typical approach is one or two cycles per year, each consisting of 10 mg/day subcutaneously for 10–20 days. This cycling approach is based on the research protocols from Khavinson's group and the clinical experience of longevity medicine physicians. Continuous daily chronic dosing is not the evidence-supported model.

Can Epithalon extend telomeres?

In vitro studies in human fetal fibroblasts show Epithalon activates telomerase expression and extends the replicative lifespan (Hayflick limit) of cells by approximately 42% versus controls. This is a well-replicated finding in the cell biology literature. Whether this translates to meaningful telomere length extension in vivo in human subjects is biologically plausible and consistent with the animal longevity data, but direct human RCT evidence for telomere length changes is limited.

Does Epithalon increase melatonin?

Yes — restoring melatonin secretion from the pineal gland is one of Epithalon's best-evidenced effects in human subjects. Multiple studies in elderly subjects show Epithalon significantly increases nighttime melatonin levels and restores the circadian amplitude of melatonin secretion. This is distinct from supplemental melatonin (which provides exogenous melatonin) — Epithalon appears to restore the pineal gland's own melatonin production capacity.

How does Epithalon compare to other longevity peptides?

Epithalon is primarily a cellular aging and neuroendocrine regulation peptide — it addresses telomere biology and pineal gland function. GHK-Cu targets collagen and tissue repair. NAD+ precursors target mitochondrial function and sirtuin pathways. GH secretagogues (ipamorelin, sermorelin) target the GH/IGF-1 axis. These are mechanistically distinct and largely complementary — comprehensive longevity protocols typically combine multiple interventions targeting different hallmarks of aging.

Where can I get Epithalon?

In the US, Epithalon is available through longevity medicine physicians who prescribe compounded Epithalon from licensed 503A compounding pharmacies. A growing number of online longevity and peptide clinics offer Epithalon as part of their anti-aging protocols — look for clinics with dedicated longevity medicine programs. International access through European longevity clinics is also available. Never use research chemical grade Epithalon for injection. Our best peptide clinics guide covers top-rated providers, or use our provider comparison tool.

Is Epithalon legal?

In the US, Epithalon is not FDA-approved but is not a scheduled controlled substance. It is legally available through licensed compounding pharmacies with a physician prescription. It cannot be legally sold as a dietary supplement or food product. Internationally, its legal status varies — it is widely used in European longevity medicine and is legally available in many countries.